Product Information
DORZOLAMIDE HCL 2% EYE DROPS is a generic product labeled by Fosun Pharma USA Inc., priced at $0.8348 per ML under NDC 72266019701. Its NADAC has been published 160 times since Sep 13, 2023.
FDA first approved this application on Jan 27, 2022. Its Orange Book therapeutic-equivalence code is AT.
Strength
20 mg/mL
Manufacturer
Fosun Pharma USA Inc.NDC
72266019701
Classification
Generic
Dosage Form
SOLUTION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
DORZOLAMIDE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215660FDA Approved
1/27/2022
TE Code
AT
On Market Since
1/23/2023
Pharmacological Classes
Price Statistics
The NADAC for DORZOLAMIDE HCL 2% EYE DROPS has been published 160 times since Sep 13, 2023, and over the history we have for it it has declined 35.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8348 per ML |
|---|---|
| All-time high | $1.5851 (Nov 13, 2024) |
| All-time low | $0.8212 (Jul 22, 2026) |
| 52-week high | $0.9950 |
| 52-week low | $0.8212 |
| Median price | $1.1438 |
| Average price | $1.1596 |
| Largest weekly change | +42.1% (Sep 18, 2024) |
| Weeks tracked | 160 |
| Tracking since | Sep 13, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dorzolamide Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fosun Pharma USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dorzolamide Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DORZOLAMIDE HCL 2% EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for DORZOLAMIDE HCL 2% EYE DROPS, manufactured by Fosun Pharma USA Inc., is $0.8348 per ML (NDC 72266019701), effective Sep 30, 2026.
How has the price of DORZOLAMIDE HCL 2% EYE DROPS changed over time?
Over the history we have for it, the NADAC for DORZOLAMIDE HCL 2% EYE DROPS has declined 35.9%. It has been tracked across 160 weekly CMS publications since Sep 13, 2023.
What are the highest and lowest recorded NADAC prices for DORZOLAMIDE HCL 2% EYE DROPS?
Since Sep 13, 2023, the NADAC for DORZOLAMIDE HCL 2% EYE DROPS has ranged from a low of $0.8212 (Jul 22, 2026) to a high of $1.5851 (Nov 13, 2024), with a median of $1.1438 per ML.
Are there cheaper alternatives to DORZOLAMIDE HCL 2% EYE DROPS?
No other NADAC-published product currently shares the active ingredient and strength of DORZOLAMIDE HCL 2% EYE DROPS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DORZOLAMIDE HCL 2% EYE DROPS?
DORZOLAMIDE HCL 2% EYE DROPS (NDC 72266019701) is labeled by Fosun Pharma USA Inc., and CMS classifies it as a generic product.